Citius Pharmaceuticals Resubmits LYMPHIR™ License Application

Citius Pharmaceuticals (CTXR) has released an update.

Citius Pharmaceuticals, Inc. has announced the resubmission of its Biologics License Application to the FDA for LYMPHIR™, aimed at treating adults with relapsed or refractory cutaneous T-cell lymphoma. This move signals a significant step forward for the company and holds promise for individuals affected by this challenging condition.

For further insights into CTXR stock, check out TipRanks’ Stock Analysis page.